Quincey James 4

What Happened
Quincey James, a member of Pfizer's Board of Directors, was granted 1,595.307 units of a deferred award on 2026-06-26. Each unit represents one phantom share valued at $24.29, for a total reported grant value of $38,750. This was an award/derivative grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; filing date (Form 4): 2026-06-30 (timely filing).
• Transaction type/code: Award/Grant (A) — derivative phantom share units.
• Units granted: 1,595.307 phantom shares; price/value used: $24.29 per unit; total value: $38,750.
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — Each unit equals one phantom share of common stock. F2 — Units are deferred director compensation (including dividend equivalents) and will be settled in cash or common stock at the director’s election following retirement from the Board.
• No exercise, sale, or tax-withholding reported in this filing.

Context
This is a deferred compensation award for a director (phantom/share units) and will be settled later in cash or stock upon the director’s retirement. Such awards reflect compensation arrangements rather than immediate purchases or sales of common stock and do not, by themselves, indicate a near-term trading signal.